WallStSmart

Ensysce Biosciences Inc (ENSC)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Ensysce Biosciences Inc generates 534% more annual revenue ($4.71M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs -250.4%. ENSC earns a higher WallStSmart Score of 31/100 (F).

ENSC

Avoid

31

out of 100

Grade: F

Growth: 5.3Profit: 2.0Value: 6.7Quality: 4.5
Piotroski: 2/9Altman Z: -29.26

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ENSCUndervalued (+59.5%)

Margin of Safety

+59.5%

Fair Value

$1.01

Current Price

$0.27

$0.74 discount

UndervaluedFair: $1.01Overvalued

Intrinsic value data unavailable for RVMD.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ENSC1 strengths · Avg: 10.0/10
Debt/EquityHealth
-0.7210/10

Conservative balance sheet, low leverage

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.299/10

Conservative balance sheet, low leverage

Areas to Watch

ENSC4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$4.56M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Return on EquityProfitability
-1149.0%2/10

ROE of -1149.0% — below average capital efficiency

RVMD4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : ENSC

The strongest argument for ENSC centers on Debt/Equity.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : ENSC

The primary concerns for ENSC are EPS Growth, Market Cap, Piotroski F-Score.

Bear Case : RVMD

The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.

Key Dynamics to Monitor

ENSC profiles as a turnaround stock while RVMD is a value play — different risk/reward profiles.

RVMD carries more volatility with a beta of 1.38 — expect wider price swings.

ENSC is growing revenue faster at -27.2% — sustainability is the question.

ENSC generates stronger free cash flow (-4M), providing more financial flexibility.

Bottom Line

ENSC scores higher overall (31/100 vs 24/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Ensysce Biosciences Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Ensysce Biosciences, Inc., a clinical-stage biotechnology company, is dedicated to the development of various prescription drugs. The company is headquartered in La Jolla, California.

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?